- Home
- RMCF vs BOLD Comparison
RMCF vs BOLD Comparison
Compare RMCF & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMCF | BOLD |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 25.7M |
| IPO Year | 2024 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RMCF | BOLD |
|---|---|---|
| Price | $2.34 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 29.0K | ★ 51.0K |
| Earning Date | 01-13-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.12 | $0.96 |
| 52 Week High | $2.99 | $1.78 |
Technical Indicators
Market Signals| Indicator | RMCF | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 47.14 |
| Support Level | $1.47 | $1.10 |
| Resistance Level | $2.59 | $1.19 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 47.29 | 29.17 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.